Pfizer Inc announced that booster doses of its COVID-19 vaccine can be given along with its pneumonia vaccine and that they produced a strong safety and immune response in people 65 and older in a late-stage study.
The study, started in May, tested the company’s next-generation pneumococcal conjugate vaccine, PREVNAR 20, with a third dose of the Pfizer-BioNTech COVID-19 vaccine in 570 participants.
The aim of the study was to test the safety of the combination and the immune response after adding the pneumonia vaccine to the existing COVID-19 vaccine.
The company stated that the responses obtained with PREVNAR 20 and the booster dose of the vaccine against COVID-19 they were similar when given together or with placebo.
The data provides evidence supporting the possibility of administering PREVNAR 20 and the company’s COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said.
PREVNAR 20 It was approved by the US Food and Drug Administration (FDA) in June last year to help protect adults against most invasive pneumococcal diseases and pneumonia.
Study participants were recruited from the vaccine study against COVID-19, which is in its final phase, and those who had received the second dose of the company’s COVID-19 vaccine at least six months before entering the co-administration study.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
